Barclays’s Ascendis Pharma A/S ASND Stock Holding History

Barclays’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-72,500	Closed	-$11M	–	4859
2024 Q1	$11M	Buy	72,500 +50,000	+222%	+$7.14M	﹤0.01%	1325
2023 Q4	$2.83M	Buy	+22,500	New	+$2.24M	﹤0.01%	2624
2021 Q4	–	Sell	-38,300	Closed	-$6.1M	–	4117
2021 Q3	$6.1M	Buy	+38,300	New	+$5.24M	﹤0.01%	1495
2019 Q2	–	Sell	-67,000	Closed	-$7.89M	–	6924
2019 Q1	$7.89M	Buy	67,000 +28,900	+76%	+$2.53M	0.01%	1374
2018 Q4	$2.39M	Buy	+38,100	New	+$2.39M	﹤0.01%	2233

Other funds holding ASND

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

ARS Investment Partners New York $2.23B AUM 74.02% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Braun Stacey Associates New York $3.48B AUM 48.73% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Barclays's ASND Position: Q3 2026 in Review

Barclays reduced its Ascendis Pharma A/S (ASND) stake by 41% in Q3 2026, selling an estimated $7.97M and leaving 45,094 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Barclays first reported a position in ASND in Q3 2017 and has held it in 37 quarters since. The position peaked at $20.4M in Q2 2026. 123 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

Barclays held 45,094 shares of Ascendis Pharma A/S worth $10.3M as of Q3 2026.
Barclays sold 31,446 Ascendis Pharma A/S shares in Q3 2026, an estimated $7.97M.
Ascendis Pharma A/S made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1628 holding.
Barclays first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 37 quarters since.
Barclays's Ascendis Pharma A/S position peaked at $20.4M in Q2 2026.
123 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.